Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Aditya Raghunath

Bristol-Myers Squibb Stock Rises on Anthropic AI Deal. Why This Could Actually Be a Key Upside Catalyst.

Bristol-Myers Squibb (BMY) just handed investors a compelling new reason to pay attention to BMY stock, and it could matter more than the market is giving it credit for. The pharmaceutical giant's new artificial intelligence (AI) partnership with Anthropic could be a key catalyst, not just a headline — and when you layer it on top of the company's already strong pipeline momentum, the case for owning this blue-chip stock into 2030 gets a lot more interesting.

Let's take a closer look.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.